← FDA DRUG APPROVALS

FDA BLA · BLA761398

CONEXXENCE

denosumab

Sponsor: FRESENIUS KABI USA LLC

APPLICATION
BLA761398
TYPE
BLA
ORIGINAL APPROVAL
2025-03-25
LATEST ACTION
2025-10-29
ROUTE
SUBCUTANEOUS
DOSAGE FORM
INJECTION
MARKETING STATUS
Prescription

Products

CONEXXENCEPrescription
DENOSUMAB-BNHT 60MG/ML · INJECTION
BOMYNTRAPrescription
DENOSUMAB-BNHT 120MG/1.7ML (70 MG/ML) · INJECTION

Approval history

2025-10-29Efficacy · Original · standardLetterAP
2025-03-25UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →